Month Year
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
Month Year
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
Jan 30, 2020- First-of-its-kind technology addresses critical need to eliminate mitral regurgitation when surgery or mitral repair is not an option- Tendyne valve provides relief from heart failure symptoms and quality-of-life improvement in high-surgical-risk patients- Together with MitraClip™, Tendyne expands Abbott's market-leading portfolio of innovative minimally invasive mitral valve solutions- Jan 24, 2020- Abbott's Infinity™ DBS is the first FDA approved directional Deep Brain Stimulation (DBS) system to allow targeting of a specific area of the brain that is critical to motor functions- Approximately 60,000 Americans are diagnosed with Parkinson's disease each year[i]
- Jan 23, 2020- BOLD study found that BurstDR™ stimulation waveform reduced the negative psychological effects associated with a person's chronic pain at six-month follow up by 62%- Data were presented at the 2020 North American Neuromodulation Society (NANS) annual meeting- Proclaim XR uses Abbott's proprietary BurstDR technology to achieve chronic pain relief
- Jan 22, 2020- Fourth-quarter sales growth of 7.1 percent; organic sales growth of 8.5 percent- Fourth-quarter GAAP EPS growth from continuing operations of 59.5 percent and adjusted EPS growth from continuing operations of 17.3 percent- Several businesses achieved double-digit sales growth- Forecast reflects continued top-tier sales and earnings growth for 2020
- Jan 13, 2020- New clinical trial will assess first-of-its-kind MitraClip™ transcatheter mitral valve repair against current standard of care surgery in a new, expanded patient population- If successful, the REPAIR MR study has potential to expand MitraClip's current indication (patients at prohibitive risk for surgery) to also include patients at moderate risk